EFFICACY AND SAFETY OF CP-86,325 (25 MG/DAY) IN TYPE II DIABETES

CP-86,325（25 毫克/天）治疗 II 型糖尿病的功效和安全性

• 批准号: 3783416
• 负责人: MARK S FEINGLOS
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3783416
• 关键词: diabetes mellitus therapy; dosage; drug /agent; drug screening /evaluation; human subject; human therapy evaluation; metabolism disorder chemotherapy; noninsulin dependent diabetes mellitus

The purpose of this study is to evaluate the safety and efficacy of CP-86,325 (25 mg/day) in the treatment of patients with type II diabetes.

本研究的目的是评价 CP-86，325（25 mg/天）治疗II型糖尿病患者。